Similar articles

• [Malignant pheochromocytoma: blood pressure controlled by labetalol].

  Sugano O, Hirano J, Hirano K, Kubota Y, Numasawa K, Kawamura S. Sugano O, et al. Nihon Hinyokika Gakkai Zasshi. 1984 Mar;75(3):523-7. Nihon Hinyokika Gakkai Zasshi. 1984. PMID: 6471663 Japanese. No abstract available.
• [Clinical effects of labetalol on pheochromocytoma].

  Yoshinaga K, Arakawa K, Ando H, Iai F, Ikeda M. Yoshinaga K, et al. Horumon To Rinsho. 1983 Feb;31(2):183-92. Horumon To Rinsho. 1983. PMID: 6340865 Clinical Trial. Japanese. No abstract available.
• [Clinical effects of labetalol in 21 patients with phaeochromocytoma (author's transl)].

  Yoshinaga K, Arakawa K, Ikeda M, Ebihara T, Oe N. Yoshinaga K, et al. Horumon To Rinsho. 1981 Apr;29(4):515-22. Horumon To Rinsho. 1981. PMID: 7296922 Japanese. No abstract available.
• [Drug therapy of pheochromocytoma].

  Coruzzi P, Novarini A. Coruzzi P, et al. Ann Ital Med Int. 1989 Jul-Sep;4(3):224-9. Ann Ital Med Int. 1989. PMID: 2577152 Review. Italian.
• Current status of labetalol, the first alpha- and beta-blocking agent.

  Kanto JH. Kanto JH. Int J Clin Pharmacol Ther Toxicol. 1985 Nov;23(11):617-28. Int J Clin Pharmacol Ther Toxicol. 1985. PMID: 2867049 Review.